<DOC>
	<DOCNO>NCT01527695</DOCNO>
	<brief_summary>This multi-centre study conduct Sweden Finland . Up 24 male and/or female patient non-childbearing potential age 45 75 year ( inclusive ) , clinical diagnosis Parkinson 's Disease randomise study allow 20 patient complete study.The study evaluate effect 8 week treatment AZD3241 microglia activation measure via PET examination .</brief_summary>
	<brief_title>PET Study Parkinson 's Disease Patients</brief_title>
	<detailed_description>A Phase IIA , Multi centre , Double-blind , Randomised , Placebo-controlled , Parallel-group Study Assess Effect 8 Weeks Treatment Oral AZD3241 Microglia Activation , Measured Positron Emission Tomography ( PET ) , Patients Parkinson 's Disease</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Female male patient age 45 75 year ( inclusive ) day enrolment ( Visit 1 ) Female patient must negative pregnancy test Screening , must lactate must non childbearing potential , confirm Screening Male patient willing use barrier contraception , eg , condom , even partner postmenopausal , surgically sterile use accepted contraceptive method , administration first dose investigational The clinical diagnosis patient must meet criterion `` diagnosis idiopathic Parkinson 's disease '' accord modify UKPDS Brain Bank criterion ( see Appendix E ) Modified Hoehn Yahr stage 1 2 Diagnosis unclear suspicion Parkinsonian syndromes exists , secondary Parkinsonism ( cause drug , toxin , infectious agent , vascular disease , trauma , brain neoplasm ) , Parkinsonplus syndromes heredodegenerative disease Patients undergone surgery treatment Parkinson 's disease ( eg , pallidotomy , deep brain stimulation , foetal tissue transplantation ) undergone brain surgery Presence significant dyskinesia , motor fluctuation , swallow difficulty loss postural reflexes Patients history nonresponse ( accord clinician patient ) adequate course Ldopa DA agonist Use pergolide , selegiline , metoclopramide , strong CYP3A4 inhibitor , CYP3A4 inducer ( include St John 's Wort ) strong CYP1A2 inhibitor inducer , within 1 month randomisation ;</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Phase IIa</keyword>
	<keyword>AZD3241</keyword>
	<keyword>microglia activation</keyword>
	<keyword>safety</keyword>
	<keyword>Pharmacodynamics pharmacokinetics analysis</keyword>
	<keyword>Parkinson patient</keyword>
</DOC>